Latest Content

The AGAVE-201 analysis found no significant bone health concerns with axatilimab in chronic GVHD, showing stable biomarkers and no increased fractures.

Bhavana Bhatnagar, DO, who moved from academic to community oncology, shares why stronger academic-community partnerships are essential for patient care

A retrospective cohort study found stable blood pressure alongside significant reductions in LVOT gradients, regardless of hypertension status.

Secondary analysis of the STAR trial finds hypoglossal nerve stimulation cut hypoxic burden by 76.6%, even in some AHI-defined nonresponders.

A proposed 2027 CMS rule would cut 340B Drug Pricing Program payments to curb Medicare drug costs and shift savings to patients.

In a cross-sectional study of US hospitals, patient financial assistance and billing policy documents averaged 10th-grade readability scores, with variation significantly associated with several attributes.

Slated to run through December 31, 2027, the Medicare GLP-1 Bridge was originally supposed to run for only 6 months.

Jody Agena, PharmD, discusses staffing, communication, and operational readiness for implementing complex oncology therapies.

The FDA advisory committee supports Moderna’s mRNA-1010 flu vaccine for adults 50-plus, with an August 5 PDUFA decision pending for mFlusiva.